GURUFOCUS.COM » STOCK LIST » USA » NAS » Atara Biotherapeutics Inc (NAS:ATRA) » Definitions » Current Ratio
Switch to:

Atara Biotherapeutics Current Ratio

: 3.10 (As of Mar. 2022)
View and export this data going back to 2014. Start your Free Trial

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Atara Biotherapeutics's current ratio for the quarter that ended in Mar. 2022 was 3.10.

Atara Biotherapeutics has a current ratio of 3.10. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Atara Biotherapeutics's Current Ratio or its related term are showing as below:

ATRA' s Current Ratio Range Over the Past 10 Years
Min: 3.1   Med: 13.81   Max: 52.75
Current: 3.1

During the past 10 years, Atara Biotherapeutics's highest Current Ratio was 52.75. The lowest was 3.10. And the median was 13.81.

ATRA's Current Ratio is ranked worse than
68.08% of 1560 companies
in the Biotechnology industry
Industry Median: 5.45 vs ATRA: 3.10

Atara Biotherapeutics Current Ratio Historical Data

The historical data trend for Atara Biotherapeutics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Current Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.23 8.04 7.43 6.31 3.64

Atara Biotherapeutics Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Current Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.51 4.42 4.29 3.64 3.10

Competitive Comparison

For the Biotechnology subindustry, Atara Biotherapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Atara Biotherapeutics Current Ratio Distribution

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Current Ratio distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Current Ratio falls into.



Atara Biotherapeutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Atara Biotherapeutics's Current Ratio for the fiscal year that ended in Dec. 2021

Current Ratio (A: Dec. 2021 )=Total Current Assets (A: Dec. 2021 )/Total Current Liabilities (A: Dec. 2021 )
=384.621/105.786
=3.64

Atara Biotherapeutics's Current Ratio for the quarter that ended in Mar. 2022 is calculated as

Current Ratio (Q: Mar. 2022 )=Total Current Assets (Q: Mar. 2022 )/Total Current Liabilities (Q: Mar. 2022 )
=314.389/101.562
=3.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atara Biotherapeutics  (NAS:ATRA) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Atara Biotherapeutics Current Ratio Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics Business Description

Atara Biotherapeutics logo
Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs.
Executives
Yarema Kristin officer: Chief Commercial Officer C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO CA 94080
Murugan Amar officer: SVP, GC & Secretary C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD,SUITE 900 SOUTH SAN FRANCISCO CA 94080
Dupont Jakob officer: EVP, Head of R&D C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063
Touchon Pascal director, officer: President and CEO C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Koppikar Utpal officer: Chief Financial Officer C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Mallik Ameet director C/O RAFAEL HOLDINGS, INC. 520 BROAD ST NEWARK NJ 07102
Renaud Ronald C Jr director C/O IDENIX PHARMACEUTICALS, INC. 60 HAMPSHIRE STREET CAMBRIDGE MA 02109
Seidenberg Beth C director
Heiden William K director C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Dobmeier Eric director C/O SAETTLE GENETICS INC 21823 30TH DRIVE SE BOTHELL WA 98021
Roncarolo Maria Grazia director C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Gallagher Carol Giltner director C/O ATARA BIOTHERAPEUTICS, INC. 3260 BAYSHORE BOULEVARD BRISBANE CA 94005
Fust Matthew K director C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Baynes Roy D. director C/O RETROPHIN, INC. 12255 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130
Berger Dietmar officer: Global Head of R&D C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080

Atara Biotherapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)